Aktienanalyse zu Spyre Therapeutics Inc (SYRE)SYRESpyre Therapeutics Inc

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Spyre Therapeutics Inc is currently not a good buy. The stock is trading at $90.36, with a 5-day change of -15.15% and an RSI of 16.467, indicating it is oversold. Despite a strong year-to-date change of +195.49% and a one-year change of +443.36%, the recent insider selling and downgrades in analyst price targets suggest caution. The main risk is the significant net losses, with a reported net income of -$69 million for Q1 2026, which raises concerns about sustainability.